



Cambridge Academy  
of Therapeutic Sciences

**ROYALTY PHARMA**

# Accelerating Bio-Innovation

Monday 04 April - Wednesday 06 April 2022 | Wellcome Genome Campus and University of Cambridge sites



**UNIVERSITY OF  
CAMBRIDGE**



**Professor Stephen J Toope**  
Vice-Chancellor,  
University of Cambridge

I am delighted to welcome you to Cambridge, and to the Accelerating Bio-Innovation conference. Cambridge has a rich history of discovery and innovation, so it is the perfect location to host this two-day event exploring some of the challenges and opportunities innovators encounter in developing new therapies.

The Cambridge Biomedical Campus, which includes University of Cambridge departments, Cambridge University Hospitals, the Royal Papworth Hospital and the Cambridge NIHR Biomedical Research Centre is the fastest growing research cluster in Europe. Recently it has been enhanced by the expansion of our Clinical Research Centre, and by the arrival of the MRC Toxicology Unit, the Cambridge Centre of Artificial Intelligence in Medicine and the Wellcome Trust-MRC Stem Cell Institute.

With the location in Cambridge of major pharmaceutical companies AstraZeneca and Otsuka, and given the closeness of GSK, as well as a rich cluster of SMEs with a therapeutic focus, Cambridge is firmly at the heart of the UK's academic and commercial drug discovery ecosystem, offering tremendous potential for the expansion of its medically relevant translational research activity.

The Cambridge Academy of Therapeutic Sciences (CATS) is positioned to deliver support across the therapeutic sciences to enable the University to widen its reach and respond to future research and studentship opportunities.

I am grateful to Royalty Pharma, a foundation partner in CATS, for co-organising this event, which brings together a powerful mix of award-winning scientists, entrepreneurs, business leaders and experts. I am certain that this conference will lay the groundwork for exciting advances in therapeutic sciences.

A handwritten signature in black ink, appearing to read 'S. Toope', written over a light blue background.

**Stephen J Toope**  
Vice-Chancellor, University of Cambridge



**Pablo Legorreta**  
Founder & CEO, Royalty Pharma

On behalf of Royalty Pharma, it is my pleasure to welcome you to the second Accelerating Bio-Innovation Conference.

The idea to collaborate with the University in Cambridge on the organization of this multi-disciplinary conference was born from our company's long history of working with leading academic institutions who are at the forefront of providing new insights into diseases and their cures.

Building on the success of the inaugural 2019 Accelerating Bio-Innovation Conference, we aim to create a stimulating environment which will inspire us to explore new ways to accelerate bio-innovation for the benefit of human health.

As we look to the future, we have the opportunity to think creatively about how to collaborate more effectively across disciplines and institutional boundaries in order to accelerate the next generation of advances in life sciences.

I thank the Cambridge Academy of Therapeutic Sciences' staff and members of the steering committee who have worked tirelessly to make sure that your participation will be rewarding.

I wish you productive discussions over the course of the conference.

A handwritten signature in black ink, appearing to read 'Pablo Legorreta', written over a light blue background.

**Pablo Legorreta**  
Founder & CEO, Royalty Pharma

## About CATS



The Cambridge Academy of Therapeutic Sciences (CATS) is a Strategic Research Initiative, established at the University of Cambridge, to maximise participation in therapeutic sciences across a very broad range of disciplines, as well as increase our ability to partner with the pharmaceutical and biotech industry.

The University of Cambridge sits at the heart of one of the world's largest technology clusters, one which has created 1,500 high-tech companies, 14 of them valued at over £800 million (US\$1 billion) and two at over £8 billion (US\$10 billion). Cambridge transcends the interface between academia and business and has a global reputation for innovation.

CATS connects world-leading academic and industry expertise to drive therapeutic development and support the education and training of the next generation of world-leading researchers. Working in partnership, CATS aims to expand the talent pipeline in therapeutic sciences through the provision of new teaching and training in the area, including a flagship Master's programme in Therapeutic Sciences which welcomed its first cohort of students in 2019.

CATS is home to the Cambridge Alliance on Medicines Safety (CAMS), a pre-competitive industry-academia partnership established to build an active research programme around the safety of medicines and invigorate the science underpinning the assessment of toxicology. Acting as a portal into University of Cambridge, CATS welcomes interaction with potential industry partners at all levels and provides key support mechanisms to enable research into therapeutics and diagnostics to flourish.

For more information visit [www.ats.cam.ac.uk](http://www.ats.cam.ac.uk)

## About Royalty Pharma plc

### ROYALTY PHARMA

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.

Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Johnson & Johnson's Tremfya, Astellas' and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.

For more information visit [www.royaltypharma.com](http://www.royaltypharma.com)

## Conference steering committee

The Accelerating Bio-Innovation conference has been organised by the Cambridge Academy of Therapeutic Sciences in partnership with Royalty Pharma.

We would like to thank our organising committee for their advice and help putting this exciting programme together:

**Michael Anstey**

Partner, Cambridge Innovation Capital

**Andy Dickinson**

Chief Financial Officer, Gilead

**Anne Ferguson-Smith**

Cambridge Pro-Vice Chancellor for Research and International Partnerships

**Arjun Goyal**

Partner, Vida Ventures

**Laura Itzhaki**

Co-Director of Cambridge Academy of Therapeutic Sciences and Head of Department of Pharmacology

**Pablo Legorreta**

Founder and CEO, Royalty Pharma

**Mark Lewisohn**

Group Managing Director, UBS and Deputy Chair of the University of Cambridge Council

**Osman Mardin**

Managing Director, Sardis Capital

**Andy Neely**

Cambridge Pro-Vice-Chancellor for Entrepreneurship and Business Relations

**Meghana Patel**

Executive Manager, Cambridge Academy of Therapeutic Sciences

**Jim Reddoch**

Executive Vice President, Co-Head Research & Investments and Chief Scientific Officer, Royalty Pharma

**Iain Thomas**

Head of Life Sciences, Cambridge Enterprise

# Agenda

TRANSLATION OF RESEARCH

BUSINESS INNOVATION

FUTURE OF DISCOVERY

## Monday 04 April Fitzwilliam Museum

Coaches depart at 16:45 and 17:40 from Wellcome Genome Campus to Fitzwilliam Museum

**17.30** Registration  
Founder's Entrance, Fitzwilliam Museum

Exclusive Private Viewing of *Hockney's Eye*  
With Museum Curators

**18.30** Drinks & Canapés  
Served in the Courtyard & Armoury

**19.00** Welcome by Jim Reddoch

**19:05** Featured talk: Zoologist's Guide to the Galaxy  
Speaker: Arik Kershenbaum

**19:20** Featured talk:  
Building a Broad Gene Therapy Pipeline  
Speaker: Alexandria Forbes

**19.35** Drinks and Standing Dinner

**21.00** Evening Concludes

Coaches depart at 20:30 and 21:00 from Fitzwilliam Museum to Wellcome Genome Campus

## Tuesday 05 April Wellcome Genome Campus

Coaches depart at 07:00, 07:30 and 08:00 from University Arms Hotel to Wellcome Genome Campus

**07:30** Continental Breakfast  
Wellcome Genome Campus conference facility

**08:00** Registration  
Wellcome Genome Campus conference facility

Session Chair: Anne Ferguson-Smith

**09:00** Welcome and Opening Remarks  
Speaker: Stephen Toope

**09:15** The Transformation of GSK  
David Redfern – Fireside chat with Chris Hite

**09:45** Artificial Biology and Skinny Genes  
Speakers: Jason Chin & Sadaf Farooqi

**10:20** From Targets to Drugs  
Speakers: Allan Bradley & Andy Plump

**11:00** Break

Session Chair: Laura Itzhaki

**11:20** Defying Aging  
Speakers: Wolf Reik, Gene Kinney, Jane Grogan & Laura Pellegrini

**12:10** Targeting the Undruggable  
Craig Crews – Fireside chat with Chris Torrance

**12:45** Lunch & Social

## Accelerating Bio-Innovation

Monday 04 April - Wednesday 06 April 2022

Wellcome Genome Campus and University of Cambridge sites

[@CambridgeATS](#) | [#AccBioInno2022](#)



Session Chair: Arjun Goyal

**13:45** **What's Interesting to Investors**  
Speakers: Oleg Nodelman, Nina Kjellson & Otello Stampacchia

**14:25** **Next-Gen Immuno Oncology**  
Speakers: Mary Lynne Hedley, Iraj Ali & Bassil Dahiyat

**15:05** **How Pfizer Innovates**  
Deborah Baron – Fireside chat with Jim Reddoch

**15:30** **Break**

Session Chair: Jim Reddoch

**15:45** **The Power of Epigenetics**  
Speakers: Tony Kouzarides, Rab Prinjha & Anne Ferguson-Smith

**16:30** **The Acceleron Story**  
Habib Dable – Fireside chat with Chris Hite

**17:00** **Keynote: An Academic Entrepreneur's Journey**  
Speakers: Siddhartha Mukherjee & Tim Springer

**17:30** **The Wellcome Campus at Hinxton**  
Speaker: Peter J Pereira Gray

**17:35** **Closing of day one**

Coaches depart at 17:45 and 18:00 from Wellcome Genome Campus to University Arms Hotel

Coaches depart at 18:00 and 18:15 from Wellcome Genome Campus to King's College, Cambridge

**19:00** **Drinks Reception: King's College, Cambridge**

**19:15** **Organ Recital at King's College chapel**  
Paul Greally, organ scholar at King's College, Cambridge

**19:45** **Formal Dinner: King's College, Cambridge**

**Seeing the Bio-Innovation World Through Global Glasses**

Speaker Siddhartha Mukherjee

**Choir: The Gentlemen of St John's College**

Coaches depart at 22:30, 23:00, 23:30 and 00:00 from King's College to Wellcome Genome Campus

## Wi-Fi

To access the free Wi-Fi simply join the 'Conference Guest' network. Then follow the on screen instructions to register up to five devices for seven days of free Wi-Fi access.

To complete registration you will receive an email, which you will need to validate.

Conference Guest Wi-Fi is available in the Conference Centre, Hall and residential bedrooms.

Wednesday 06 April

## Wellcome Genome Campus

Coaches depart at 07:00, 07:30 and 07:45 from University Arms Hotel to Wellcome Genome Campus

**07:30** **Continental Breakfast**  
Wellcome Genome Campus conference facility

Session Chair: Andy Neely

**08:30** **Keynote: A Pharma Growth Story**  
Pascal Soriot – Fireside chat with Pablo Legorreta

**09:10** **Themes in Oncology**  
Speakers: Axel Hoos, Steve Jackson & Anthony Sun

**09:50** **Cultivating Innovation from Academia**  
Speakers: Mike Anstey, Melanie Lee, Greg Raskin, Clare Bryant & Jason Mellad

**10:30** **Break**

Session Chair: Meghana Patel

**10:50** **Innovation at Amgen**  
David Reese – Fireside chat with Mike Rea

**11:25** **Learnings from COVID-19 Pandemic for the Future**  
Speakers: Sharon Peacock & Kate Bingham

**11:45** **Transforming Abbvie**  
Henry Gosebruch – Fireside chat with Osman Mardin

**12:15** **Lunch & Social**

## Artificial Intelligence mini conference

Session Chair: Matthias Evers

**13:05** **Setting the Stage**  
Speaker: Matthias Evers

**13:10** **Atomwise's Approach**  
Speaker: Abraham Heifets

**13:35** **Benevolent's Approach**  
Speaker: Joanna Shields

**14:00** **The Investor Perspective**  
Speaker: Michael Secora

**14:25** **Exscientia's Approach**  
Speaker: Andrew Hopkins

**14:50** **Closing Comments for Conference**

Coaches depart at 15:00 and 15:15 from Wellcome Genome Campus to University Arms Hotel.

# Speakers and Chairs

For extended biographies, please visit [www.ats.cam.ac.uk](http://www.ats.cam.ac.uk)



## Iraj Ali

TUESDAY, 14:25

CEO, Achilles Therapeutics plc

Iraj Ali has been CEO of Achilles Therapeutics since 2018. Previously he served as a Managing Partner of Syncona Ltd. During his tenure at Syncona he served as an investment partner and Board member of Nightstar Therapeutics and Blue Earth Diagnostics. Prior to that he was an Associate-Principal at McKinsey & Company where he was involved in several major pharmaceutical launches across developed and emerging markets. He has also held roles in scientific research: EMBO Research Scholar (UCSC), Drug Discovery Scientist (RiboTargets, Cambridge). Iraj has a PhD in Biochemistry from University of Cambridge.



## Michael Anstey

WEDNESDAY, 09:50

Partner, Cambridge Innovation Capital (CIC)

Dr. Michael Anstey is a Partner at CIC specialising in life science investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group's (BCG) Toronto office. Prior to BCG, Michael worked at Oxford Capital Partners, where he focused on investing in early-stage life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology from University of Oxford. Michael manages CIC's investments in Bicycle Therapeutics (NASDAQ: BCYC), Congenica, Immutrin, PredictImmune, PolyProx Therapeutics, Sense Bio, Start Codon and Storm Therapeutics.



## Deborah Baron

TUESDAY, 15:05

Senior Vice President of Worldwide Business Development, Pfizer Inc.

Deborah Baron currently serves as Senior Vice President, Worldwide Business Development for Pfizer Inc., where she leads all business development activities including prioritizing opportunities, managing evaluations, and executing transactions. Ms. Baron's team covers a wide range of transaction types including venture investments, collaborations, license agreements, mergers and acquisitions, and divestitures. Prior to this role, Ms. Baron held positions of increasing responsibility at Pfizer, including leading business development activities in the company's Primary Care and Emerging Markets businesses. Before joining Pfizer, Ms. Baron was an associate principal in the New York office of management consulting firm, McKinsey and Company, and previously worked as a manufacturing engineer at The Stanley Works. Ms. Baron received a bachelor's degree in mechanical engineering from MIT and an M.BA from the MIT Sloan School of Management.



## Kate Bingham

WEDNESDAY, 11:25

SV Health Managers LLP

Kate co-leads SV's biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market. Kate's investments, many of which are examples of SV's company creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas in companies in the UK, EU and US. Kate played an active role in setting up the Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee.

Prior to joining SV, Kate worked for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.

In May 2020 Kate was appointed Chair of the UK Vaccine Taskforce reporting to the Prime Minister to lead UK efforts to find and manufacture a COVID-19 vaccine stepping down as Chair in December 2020. On December 8th 2020 the UK started COVID-19 vaccinations – the first Western country to do so. She was awarded a DBE in the Queen's Birthday Honours in June 2021 for services to the procurement, manufacture and distribution of COVID-19 vaccines.



## Allan Bradley

TUESDAY, 10:20

Director of Research, Department of Medicine, University of Cambridge

Allan Bradley, PhD is a Professor in the Cambridge Institute of Therapeutic Immunology and Infectious Disease at University of Cambridge. As a PhD student at University of Cambridge, he conducted foundational work on embryonic stem cells which contributed to the 2007 Nobel Prize awarded for ES cell technology.

Professor Bradley is a serial entrepreneur, in 1995 he established Lexicon Genetics to industrialize mouse knockouts for drug-target discovery. Lexicon Genetics was floated on the NASDAQ five years later. In 2000 he founded Spectral Genomics which developed micro-arrays for diagnosis of human disorders and was eventually sold to Perkin Elmer Inc. In 2010 he founded Kymab Limited, serving as Director and CSO. Kymab successfully engineered the most advanced mouse platform for discovery of human therapeutic antibodies and was recently acquired by Sanofi for \$1.45bn. In 2017, he founded PetMedix Ltd, where he serves as the CSO & Director. PetMedix develops therapeutic antibodies for dogs and cats.



## Clare Bryant

WEDNESDAY, 09:50

Professor of Innate Immunity, University of Cambridge

The Bryant group collaborates closely with academics in the USA, Europe and Australia to perform cutting edge innate immunity research. A vital part of the Bryant group's work is to forge, and maintain, strong collaborations with the pharmaceutical industry to translate their research into medicines. The group has close links to Genentech (Professor Bryant was a visiting professor there in 2016 and 2017). She was also seconded to GSK in Stevenage as part of their Immunology Catalyst program for 3 years to forge stronger links with academia. Professor Bryant has a drug discovery program with Apollo Therapeutics looking for novel therapeutics against TLR4 as potential treatments for Alzheimer's disease and asthma. Professor Bryant has a start up company, has collaborative grants with different pharmaceutical companies and she currently is on the scientific advisory board and/or consults for a number of biotech companies in the UK and the USA.



## Jason Chin

TUESDAY, 09:45

Professor of Chemistry and Chemical Biology, University of Cambridge

Jason Chin is a Programme Leader at the Medical Research Council Laboratory of Molecular Biology (MRC-LMB), where he is also a Head of the Centre for Chemical & Synthetic Biology (CCSB) and joint Head of the Division of Protein and Nucleic Acid Chemistry. He is a Professor of Chemistry and Chemical Biology at the University of Cambridge Department of Chemistry, a founding Associate Faculty Member in Synthetic Genomics at the Wellcome Sanger Institute, and a fellow and director of studies in Biochemistry at Trinity College, Cambridge. Jason was an undergraduate at Oxford, obtained his PhD as a Fulbright grantee from Yale, and was a Damon Runyon Fellow at Scripps. He became an EMBO Young Investigator in 2005 and a tenured group leader in 2007 at MRC LMB. He was awarded the Francis Crick Prize by the Royal Society (2009), Royal Society of Chemistry's Corday Morgan Prize (2010), the European Molecular Biology Organization's (EMBO) Gold Medal (2010), the Louis-Jeantet Young Investigator Career Award (2011) and Sackler International Prize in the Physical Sciences (2019). Jason was elected to the European Inventor Hall of Fame (2013) and to Fellowship of the Academy of Medical Sciences (2016).



## Craig Crews

TUESDAY, 12:10

John C. Malone Professor of Molecular, Cellular and Developmental Biology, Yale University

Dr. Crews is the John C. Malone Professor of Molecular, Cellular and Developmental Biology and holds joint appointments in the departments of Chemistry and Pharmacology at Yale University. He graduated from the U.Virginia with a BA in Chemistry and received his PhD from Harvard University in Biochemistry. Dr. Crews has a foothold in both the academic and biotech arenas; on the faculty at Yale since 1995, his laboratory has pioneered the use of small molecules to control intracellular protein levels. In 2003, he co-founded Proteolix, Inc., whose proteasome inhibitor, Kyprolis™ received FDA approval for the treatment of multiple myeloma. Since Proteolix's purchase by Onyx Pharmaceuticals in 2009, Dr. Crews has focused on a new drug development technology, which has served as the founding intellectual property for his latest New Haven-based biotech ventures, Arvinas, Halda Therapeutics and Siduma Therapeutics. Currently, Dr. Crews serves on several editorial boards and was Editor of *Cell Chemical Biology* (2008-2018).



## Habib J. Dable

TUESDAY, 16:30

President & CEO, Acceleron Pharma Inc.

Mr. Dable joined Acceleron in December 2016, serving as President and CEO until its sale to Merck & Co. in November 2021. Previously, Mr. Dable served as President of U.S. Pharmaceuticals at Bayer AG. In addition to President of U.S. Pharmaceuticals, he also served as Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology, Global Launch Team Head, EYLEA®, Global Head, Neurology and Ophthalmology; Vice President, Regional Head, Hematology and Cardiology; Director of International Sales and Marketing, Biologics Research; and Head of Strategic Planning, Pharmaceuticals, Japan.

As Executive Vice President, Global Head Specialty Medicine, Mr. Dable led the launch of various blockbuster brands, including EYLEA®, Stivarga®, and Xofigo®. Mr. Dable also managed research and development collaborations and served on Joint Steering Committees with companies such as Algeta ASA, Orion Corporation and Regeneron Pharmaceuticals.



## Bassil Dahiyat

TUESDAY, 14:25

President & CEO, Xencor Inc

Bassil Dahiyat, PhD, has been Xencor's president and chief executive officer since the Company's incorporation in August 1997, and is the co-founder of Xencor, and co-inventor of Xencor's breakthrough XmAb® technology. He has led the Company in raising over \$700 million in public and private financing, creating a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases, and establishing alliances with leading biopharmaceutical companies that has resulted in three marketed antibody therapeutics. He has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 US and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech. Dr. Dahiyat received a PhD in chemistry from Caltech and B.S. and M.S.E. degrees in biomedical engineering from Johns Hopkins University.



## Matthias Evers

WEDNESDAY, 13:05

Senior Partner, McKinsey & Company

As a scientist at heart and molecular biochemist and bioinformatician by training, Matthias is a Senior Partner in McKinsey's Hamburg office and co-leads the firm's Global Research & Development and Medical work in the Life Sciences practice as well as the cross-sectoral Innovation practice.

Since joining the firm in 2002, Matthias engaged with clients in Europe as well as in the U.S., China, and India on transforming their organizations to step-up innovation and R&D productivity. He is active in cross-industry settings with focus on innovation and science leadership (e.g., initiator of *Monastery & Minds* network, imi Horizon 2020/IHI, GapSummit, Lindau Nobel Laureate Meetings).

His work often deals with the confluence of new advances in biology and (digital) technology and focuses on collaboration across the health innovation ecosystem to tap into this 'revolution' ([www.mckinsey.com/biorev](http://www.mckinsey.com/biorev)). His clients include biotech, big pharma companies along with Private Equity/Venture Capital firms, academic medical centers, and Contract Research Organizations.



## Sadaf Farooqi

TUESDAY, 09:45

Wellcome Principal Research Fellow and Professor of Metabolism and Medicine, University of Cambridge, UK.

She is an internationally recognized Clinician Scientist who has made seminal contributions to understanding the genetic and physiological mechanisms that underlie obesity and its complications. The work of Sadaf Farooqi and her colleagues has fundamentally altered our understanding of how body weight is regulated and established that the principal driver of obesity is a failure of the control of appetite. Her work is often cited as an exemplar of how the translation of basic research into the mechanisms of disease can lead to patient benefit. Her current work focusses on the genetic basis of thinness with the aim of finding new drug targets for weight loss therapy.





## Anne Ferguson-Smith

TUESDAY, 15:45

**Pro-Vice-Chancellor for Research and International Partnerships, University of Cambridge**

Professor Anne Ferguson-Smith is the current Pro-Vice-Chancellor for Research (since 2021) and International Partnerships (from 2022) at University of Cambridge. She is the Arthur Balfour Professor of Genetics (since 2015). Formally, she was the University's Head of the Department of Genetics until December 2020. She became the President of the Genetics Society in 2021 and is a member of the UKRI BBSRC Council.

She is a mammalian developmental geneticist and epigeneticist. An expert on genomic imprinting, her team studies the epigenetic control of genome function with particular emphasis on epigenetic inheritance. She was elected to EMBO in 2006, to the UK Academy of Medical Sciences and the Society of Biology in 2012 and became a Fellow of the Royal Society in 2017. In 2014 she was awarded the Women in Science Heirloom Award for contributions to life sciences, In 2019 she was awarded the Feldberg Prize and in 2021 the Buchanan Medal and the Society for Reproduction and Fertility, Anne McLaren Distinguished Scientist Award. She is a Fellow of Darwin College, University of Cambridge.



## Alexandria Forbes

MONDAY, 19:20

**President, CEO and Founder of MeiraGTx**

Alexandria Forbes, PhD is the President, CEO and Founder of MeiraGTx (NASDAQ: MGTX). MeiraGTx, a gene therapy company with end-to-end capabilities in discovery, development and GMP manufacturing of genetic medicines, has built a broad pipeline of clinical programs, internal GMP vector and plasmid manufacturing as well as industry-leading vectorology. Prior to MeiraGTx, Dr. Forbes spent 10 years as a healthcare investor responsible for investments in biotechnology and specialty pharmaceuticals companies and was portfolio manager of the Sivik Global Life Science Fund.

Previously, Dr. Forbes was an academic scientist studying the regulation of stem cell identity and determination of cell fate. She was a Human Frontiers/Howard Hughes postdoctoral fellow at NYU Langone Medical Center and a research fellow at Duke University and at the Carnegie Institute at Johns Hopkins University. Her work identified the role of the hedgehog gene and its signaling pathway in the Drosophila embryo and adult. Dr. Forbes received her PhD in Molecular Genetics from University of Oxford, UK and attained a double first degree in Natural Sciences from University of Cambridge, UK.



## Henry Gosebruch

WEDNESDAY, 11:45

**Executive Vice President and Chief Strategy Officer, AbbVie**

Henry Gosebruch is Executive Vice President and Chief Strategy Officer at AbbVie, a global biopharmaceutical company with a current market capitalization of approximately \$250 billion and revenues of more than \$50 billion. As a member of AbbVie's Executive Leadership Team, he is responsible for Corporate Strategy, Business Development & Acquisitions, Search & Evaluation, Alliance Management, R&D decision support/portfolio analytics and AbbVie Ventures. Henry and his team have completed over 100 business development/M&A transactions and venture capital investments since 2015. His organization consists of approximately 80 colleagues globally.

Prior to his AbbVie appointment in late 2015, Henry was Co-Head of J.P. Morgan's North American M&A Group based in New York. Henry is a German citizen who graduated magna cum laude from the Wharton School at the University of Pennsylvania in 1995 with a BSE. He is a licensed CPA in Illinois and graduate of G100 Next Gen. Henry and his wife have three boys and live in Chicago.



## Arjun Goyal

TUESDAY, 13:45 (CHAIR)

**Co-Founder and Managing Director, Vida Ventures.**

Dr. Arjun Goyal is a Co-Founder and Managing Director of Vida Ventures, a leading US-based life sciences venture capital firm with approximately \$1.7 billion in AUM. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Arjun serves as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Affini-T, Alterome Therapeutics and Centessa Pharmaceuticals (NASDAQ: CNTA) and has played key roles in Vida Venture's investments in Homology Medicines (NASDAQ: FIXX), Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer).

Before co-founding Vida Ventures in 2017, Arjun was a life sciences investor at 5AM Ventures. Arjun received his B.Sc. in Medical Science, Diploma in French and his MBBS degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his M.Phil. in Bioscience Enterprise from University of Cambridge and his MBA from Harvard Business School. Arjun has received multiple awards for his work including the Advance Award for Technology & Entrepreneurship from the Australian Government. He is a co-inventor on one patent and had served on the editorial board of an international scientific journal. He serves on the Committee for the American Australian Association Education Fellowship.



## Jane Grogan

Chief Scientific Officer, Graphite Bio, Inc.

TUESDAY, 11:20

Dr. Jane Grogan is the Chief Scientific Officer of Graphite Bio, a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop one-time cures for patients. Prior to joining Graphite Bio, Dr. Grogan served as Chief Scientific Officer at ArsenalBio, building programmable CAR-T cell therapies; and as head of adaptive immunity at Genentech leading multiple immuno-oncology programs. Dr. Grogan is widely recognized as the founder and original host of the popular podcast series *Two Scientists Walk into a Bar* and is on the board of the new series *Lost Women of Science*.



## Mary Lynne Hedley

Senior Scientific Fellow, Broad Institute

TUESDAY, 14:25

Mary Lynne serves as a strategic advisor to scientists across the Broad Institute. She was most recently co-founder, Director, President and Chief Operating Officer of TESARO, a biotechnology company focused on the development and global commercialization of medicines to treat patients with cancer. Prior to its acquisition by GSK in 2019 for \$5.1 billion, TESARO had built a robust pipeline of products and drug candidates and had received multiple drug approvals from FDA and European regulatory authorities. Dr. Hedley is an immunologist by training and holds a PhD in Molecular and Cellular Immunology from UT Southwestern Medical Center. She is listed as an inventor on over 50 patents and patent applications and has received several honors, including, the Ernst & Young (EY) Entrepreneur of the Year in 2017 for the United States, and represented the country at the International EY entrepreneur of the year event in 2018. She won the New England Venture Capital Association 2016 Entrepreneur of the Year, was voted one of the Ten Most Influential Women in Biotechnology in 2013.



## Abraham Heifets

CEO, Atomwise, Inc.

WEDNESDAY, 13:10

Abraham Heifets is the CEO and co-founder of Atomwise, which uses artificial intelligence to help discover new medicine. Abraham was a Massey Fellow at the University of Toronto and the Ontario Brain Institute, where his doctoral work used machine learning to help plan organic syntheses, a long-standing challenge in chemistry. Previously, Abraham researched high-performance data processing at IBM's T.J. Watson Research Center and contributed to the artificial intelligence system of the world-champion robotic soccer team at Cornell University, from which he holds two previous degrees. Abraham has presented his work at the National Institutes of Health, the American Chemical Society, and the Association for the Advancement of Artificial Intelligence. He is an author on 19 papers, patents, and patent applications.



## Christopher Hite

Executive Vice President & Vice Chairman, Royalty Pharma plc

TUESDAY, 09:15 & 16:30

Mr. Hite has over 25 years of experience advising biopharmaceutical companies on mergers and acquisitions and capital formation. Prior to joining Royalty Pharma in 2020, Mr. Hite was an investment banker at Citi where he was the Global Head of Healthcare for nearly 12 years and most recently a Vice Chairman of Banking, Capital Markets and Advisory (BCMA) and also sat on the Executive Committee of BCMA. Prior to joining Citi, Mr. Hite was the Global Head of Healthcare Investment Banking at Lehman Brothers. Mr. Hite serves on the Board of Advisors of Faster Cures, a center of the Milken Institute, and served on the Board of Directors of Acceleron Pharma Inc. (Nasdaq: XLRN) until its acquisition by Merck in November 2021 for \$11.5 billion. Mr. Hite has a BS from Lehigh University and a JD and MBA from the University of Pittsburgh.



## Axel Hoos

CEO, Scorpion Therapeutics, Inc.

WEDNESDAY, 09:10

Dr. Axel Hoos is CEO of Scorpion Therapeutics, a next-generation oncology company focused on precision medicine 2.0 with the potential to address many of the current white spaces in cancer care.

Previously, he served as Senior Vice President and Therapeutic Area Head of Oncology R&D at GlaxoSmithKline Pharmaceuticals (GSK) where he built GSK's Oncology business. Before GSK, he was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS), where he led the clinical development of the first FDA-approved checkpoint immunotherapy ipilimumab, and spearheaded the launch of Immuno-Oncology. Dr. Hoos further serves as a Director on the Board of TCR2, a cell therapy company, as Trustee on the Board of the Sabin Vaccine Institute, as member of CRI's Scientific Advisory Council, and as chairman of the Cancer Immunotherapy Consortium (CIC).



## Andrew Hopkins

CEO, Exscientia plc

WEDNESDAY, 14:25

Andrew Hopkins, DPhil is the Founder and CEO of Exscientia. He is one of the most distinguished and cited scientists in modern drug discovery. After more than a decade at Pfizer, Andrew was drawn to academia to pursue pioneering research projects applying data mining and machine learning to the pharmaceutical industry. His invention of an automated and algorithmic approach to drug design and discovery led to the founding of Exscientia. Since its founding, the Exscientia team has grown to more than 300 employees with offices around the world and has delivered the world's first three AI-designed drugs into the clinic.

Following Exscientia's successful listing on Nasdaq in October 2021, Andrew's focus as CEO is a patient-first mission to accelerate the creation of the best possible medicines with improved probability of success using AI methods to select targets, precision design new drugs and enhance patient selection.

Andrew holds a first class BSc in Chemistry from the University of Manchester and a DPhil in Molecular Biophysics from Wadham College, Oxford. He is also an honorary professor at the School of Life Sciences, University of Dundee, where he previously held Chairs in translational biology and medicinal informatics.



## Laura Itzhaki

Co-Director of Cambridge Academy of Therapeutic Sciences and Head of Department of Pharmacology, University of Cambridge

TUESDAY, 11:20

Laura's background is in Chemistry and Biochemistry. From 2003 to 2011 her group was located at the MRC Cancer Cell Unit in Cambridge UK. She moved to the University of Cambridge, Department of Pharmacology in 2013 and was appointed Professor of Structural Pharmacology in 2017. She is currently Head of Department of Pharmacology and co-Director of Cambridge Academy of Therapeutic Sciences. Her group is using protein engineering and design to interrogate and exploit proteostasis networks in the cell and thereby manipulate protein stability and disease outcome.



## Steve Jackson

University of Cambridge Frederick James Quick Professor of Biology;  
Head of Cancer Research UK Laboratories at the Gurdon Institute

WEDNESDAY, 09:10

Professor Jackson's research has identified key principles by which cells respond to and repair DNA damage and helped define how their dysfunction yields cancer and other age related diseases. Steve has received various national and international prizes, and is a Fellow of the Royal Society and the UK Academy of Medical Sciences. In 1997 Steve founded KuDOS Pharmaceuticals Ltd., serving as its part-time Chief Scientific Officer until and after its acquisition by AstraZeneca. Several KuDOS-derived drugs are in clinical trials, with the most advanced, the PARP inhibitor olaparib/Lynparza™, being a marketed drug for certain ovarian, breast, pancreatic and prostate cancers worldwide. In 2010, Steve founded Mission Therapeutics Ltd. to exploit advances in protein ubiquitylation and deubiquitylation to derive new medicines and co-founded Adrestia Therapeutics Ltd, which in late 2020 secured Series A investment by GSK and Ahren Innovation Capital.

In the Gurdon Institute Steve is currently further defining mechanisms by which cells detect, signal the presence of and repair DNA damage, with a view to delivering new fundamental biological insights and identifying opportunities for better understanding and treating cancer and other diseases.



## Arik Kershenbaum

MONDAY, 19:05

College Lecturer, University of Cambridge

Dr. Arik Kershenbaum is a zoologist, College Lecturer, and Fellow at Girton College, University of Cambridge, and an expert on animal vocal communication, which he has researched for the past 13 years, publishing more than 20 academic papers on the topic.

His first popular science book, *The Zoologist's Guide to the Galaxy* was a Times/Sunday Times Book of the Year, a BBC Science Focus magazine Best Space and Astronomy Books of the Year, received accolades from among others, Richard Dawkins and Lord Martin Rees (the Astronomer Royal), and was published in nine languages. Dr. Kershenbaum received his PhD at the University of Haifa in Israel and was a postdoctoral fellow at the National Institute for Mathematical and Biological Synthesis in the USA. Dr. Kershenbaum was Herchel Smith Research Fellow in Zoology at University of Cambridge, before taking up his position at Girton College. Dr. Kershenbaum has recently been granted a ScD from University of Cambridge for his works.



## Gene G. Kinney

TUESDAY, 11:20

President and CEO, Director, Prothena

Dr. Kinney has served as Prothena's President and CEO since September 2016. Prior to being appointed to this position he was Chief Operating Officer and Chief Scientific Officer. Dr. Kinney is a member of Prothena's founding leadership team, and between 2012 and 2016 held the position of Chief Scientific Officer and Head of Research and Development. Before joining Prothena, Dr. Kinney held positions with Elan Pharmaceuticals Inc., including Senior Vice President of Pharmacological Sciences (a position he held from 2011 to 2012), and Vice President, Pharmacology (a position he held from 2009 to 2011); while in those positions, Dr. Kinney also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy. Before joining Elan, Dr. Kinney held several senior positions at Merck Research Laboratories and Bristol-Myers Squibb, and was an Assistant Professor at the Emory University School of Medicine. Dr. Kinney earned his BA from Bloomsburg University and his M.A. and PhD from Florida Atlantic University. Dr. Kinney has served on Prothena's Board since September 2016.



## Nina Kjellson

TUESDAY, 13:45

General Partner, Canaan

Nina Kjellson has been a General Partner at Canaan since 2015 and invests in biopharma and digital health start-ups that serve high unmet needs. She has 20 years of experience funding, growing and transacting early-stage companies. Current Canaan investments include Intrepida, Pact Pharma, Tizona, Tyra and Vineti. She also serves on the board of WellTok and previously served on the boards of Labrys (acquired by Teva), Cidara (CDTX), Trius (TSX, acquired by Cubist), Eiger (EIGR), NovaCardia (acquired by Merck) and co-sponsored investments into Paratek (PRTK), Tesaro (TSRO, acquired by GSK) and Aspreva (ASPV, acquired by Galenia), along with numerous other ventures during her tenure at InterWest Partners. As a leader of Canaan's Women of Venture program, Nina is a vocal advocate for female entrepreneurs and investors. She serves as an advisor to Springboard Life Sciences, Nina Capital (no relation), The Gates Foundation and serves on the boards of Essential Access Health, Girl Effect and the Oliver Wyman Health Innovation Center. Nina is a 2018 Aspen Institute Health Innovators Fellow. Prior to InterWest and Canaan, Nina worked at Bay City Capital, Oracle Partners and the Kaiser Family Foundation. She holds a BA in human biology from Stanford University. Nina is an avid reader, is active in nature, runs, skis and loves to travel the world.



## Tony Kouzarides

TUESDAY, 15:45

Professor of Cancer Biology, University of Cambridge

Tony Kouzarides is professor of Cancer Biology at University of Cambridge. He is a Senior Group Leader at the Gurdon Institute and director/co-founder of the Milner Therapeutics Institute. Tony did his PhD at University of Cambridge and postdoctoral work at MRC Laboratory of Molecular Biology and at New York University Medical Center. His research group at the Gurdon Institute is focused on epigenetic modifications and their involvement in cancer. Tony is co-founder of Abcam plc, a research reagents supplier, based on the Cambridge Biomedical Campus, STORM Therapeutics, a drug discovery company based in on the Cambridge Babraham Campus, and Chroma Therapeutics, based in Oxford. He is the founder and director of Cambridge Gravity, the founder of a cancer charity in Spain (Vencer el Cancer) and is a Fellow of the Royal Society (FRS), the British Academy of Medical Sciences (FMedSci), the American Academy of Arts and sciences (AAAS), the Cyprus Academy of Science and a member of the European Molecular Biology organization.

He has been awarded the Wellcome Trust Award for Research in Biochemistry Related to Medicine, the Tenovus Medal, the Bodossaki Foundation prize in Biology, the Bijvoet Medal, the Biochemical Society Award, the Novartis Medal and Prize, the Heinrich Wieland Prize, the Nemitsas Prize and the Cyprus Science Excellence award.



## Melanie Lee

CEO of LifeArc

WEDNESDAY, 09:50

Melanie has pursued a 30-year career in healthcare R&D and gained leadership experience both from the biopharmaceutical industry and from the medical research charity sector. Melanie's previous roles have included Chief Scientific Officer at BTG PLC (most recently) as well as senior positions at GSK, Celltech and UCB. She has previously held Trustee appointments at Cancer Research Technology and Cancer Research UK and currently serves as a Board Trustee at Sanofi and UK Dementia Research Institute.



## Pablo Legorreta

Founder, CEO and Chairman, Royalty Pharma plc

WEDNESDAY, 08:30

Since its founding in 1996, Royalty Pharma has been the pioneer and market leader in royalty funding of life science innovation. The company's collaborations span the entire research and development ecosystem, from academic institutions, research hospitals and not-for-profits to small- and mid-cap biotechnology companies and global pharmaceutical companies. To date, Royalty Pharma has deployed more than \$20 billion of capital to advance innovation in the biopharmaceutical industry.

Mr. Legorreta is a co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry. He is also a co-founder of ProKidney, LLC, a biotech company developing pioneering therapies that has the potential to change the lives of people with chronic kidney disease.

Mr. Legorreta is also the founder and chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities.

Mr. Legorreta serves on the Board of Directors of Epizyme and on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, Brown University, the Hospital for Special Surgery, Pasteur Foundation, Open Medical Institute and Park Avenue Armory.

Prior to founding Royalty Pharma, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York.



## Osman Mardin

Managing Director, Sardis Capital

WEDNESDAY, 11:45

In an advisory career of over 30 years, Osman has served multiple Corporations, Investors, and Entrepreneurs in the US and Europe on Strategic Advisory, Mergers&Acquisitions and Private Financings, specialising in the last 25 years in the Life Sciences and Information Technology areas. Prior to founding Sardis Capital in 2002 in London, Osman was with Robertson Stephens 1998-2002 (San Francisco and London) as Managing Director and head of M&A for Europe&Israel.

Prior to Robertson Stephens, Osman was Executive Director of Lazard Frères & Cie. (Paris). Osman has a BA from Trinity College, Cambridge, and an MBA from Harvard Business School.



## Jason Mellad

CEO and Co-Founder, Start Codon

WEDNESDAY, 09:50

Jason is a scientist entrepreneur passionate about translating innovative technologies into better patient outcomes. As CEO and co-founder of Start Codon, a Cambridge based venture builder, he aims to identify the most disruptive healthcare founders and innovations worldwide, seed fund them and leverage the exceptional resources of the Cambridge cluster to de-risk and drive the success of their start-ups.

Previously he was CEO of Cambridge Epigenetix and Business Development Manager for Horizon Discovery's diagnostics division. He also served as an associate at Cambridge Enterprise, the technology transfer office of University of Cambridge.



## Siddhartha Mukherjee

TUESDAY, 17:00 &amp; 19:45

Associate Professor of Medicine, Columbia University

Siddhartha Mukherjee is a pioneering physician, oncologist, and author who has redefined our public discourse on human health, medicine and science. A profoundly influential voice in the scientific community, he is best known for his books, *The Emperor of All Maladies: A Biography of Cancer*, which won the 2011 Pulitzer Prize, and *The Gene: An Intimate History* which won international awards and was recognized by The Washington Post and The New York Times as one of the most influential books of 2016. His published works exhibit an outstanding literary skill that has left an indelible mark on our culture; *The Emperor of All Maladies* has been adapted into a documentary by filmmaker Ken Burns, and was included among Time magazine's 100 best nonfiction books of the past century.

Dr. Mukherjee's achievements as a writer and educator build upon his career as a renowned medical scholar. His groundbreaking studies into the composition and behavior of cancer cells have pushed the boundaries of modern medicine. His innovative research signals a paradigm shift in cancer pathology, and has enabled development of treatments reaching beyond current pharmaceutical models toward new biological and cellular therapies. He lives in New York City with his wife and daughters.



## Andy Neely

WEDNESDAY, 08:30 (CHAIR)

Pro-Vice-Chancellor for Enterprise and Business Relations, University of Cambridge

Professor Andy Neely OBE is the Pro-Vice-Chancellor for Enterprise and Business Relations at the University of Cambridge and former Head of the Institute for Manufacturing (IfM). He was the Founding Director of the Centre for Digital Built Britain and the Cambridge Service Alliance.

Professor Neely is widely recognised for his work on the servitisation of manufacturing, as well as his work on performance measurement and management. He received an OBE for services to Research and to University/ Industry Collaboration in 2020.



## Oleg Nodelman

TUESDAY, 13:45

Founder and Portfolio Manager, EcoR1 Capital LLC

Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With twenty years of experience in biotech investing, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to the biotechnology sector. He currently serves as a Board Member for three publicly traded companies: Prothena (NASDAQ: PRTA), a clinical-stage neuroscience company, AnaptysBio (NASDAQ: ANAB), a clinical-stage biotechnology company focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, and Nuvation Bio (NYSE: NUVB), a clinical-stage biopharmaceutical company tackling unmet needs in oncology. Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.



## Meghana Patel

WEDNESDAY, 10:50 (CHAIR)

Executive Manager, Cambridge Academy of Therapeutic Sciences, University of Cambridge

Meghana is the Executive Manager at Cambridge Academy of Therapeutic Sciences (CATS), a Strategic Research Initiative by the University of Cambridge. CATS facilitates the development of new therapeutics and supports the education and training of the next generation of world-leading researchers and entrepreneurs. She is responsible for the overall strategy and development of CATS and manages the CATS team to drive collaboration and partnership in research translation, education, training and policy. This includes working with academics across the University, industry leaders and key opinion leaders, CATS foundation partners and international associates. Meghana also works with the strategic partnership office at the University of Cambridge focussing on the development of new strategic partnerships between external organisations and Cambridge academics in the pharmaceutical and health care sector.

Meghana received a PhD from the University of Cambridge where she was a Gates Cambridge Scholar. Before joining the CATS team, she has worked as a drug discovery scientist and post-doctoral fellow at GSK and in technology commercialisation offices at LifeArc, UCL, QMUL and Imperial College London.



## Sharon Peacock

WEDNESDAY, 11:25

Professor of Public Health and Microbiology, University of Cambridge; Executive Director of the COVID-19 Genomics UK (COG-UK) consortium; Non-Executive Director on the board of Cambridge University Hospitals, NHS Foundation Trust

Sharon has raised around £60 million pounds in science funding, published more than 500 peer-reviewed papers, and has trained a generation of scientists in the UK and elsewhere. She is a Fellow of the Academy of Medical Sciences, a Fellow of the American Academy of Microbiology, and an elected Member of the European Molecular Biology Organization (EMBO). In 2015, she received a CBE for services to medical microbiology, and in 2018 she won the Unilever Colworth Prize for her outstanding contribution to translational microbiology. Sharon was recently awarded the MRC Millennium Medal 2021.



## Laura Pellegrini

TUESDAY, 11:20

Neuroscientist, MRC Laboratory of Molecular Biology, Cambridge

Laura Pellegrini is a neuroscientist at the MRC Laboratory of Molecular Biology in Cambridge. She obtained a Master in Biomedical Sciences at the University of Padua, Italy. Laura joined an international PhD program shared between the NIH (USA) and UCL (UK) in the laboratories of Professor Kirsten Harvey (UCL) and Dr. Mark Cookson (NIH) and completed her degree in Neurogenetics in 2017. During the PhD she studied genetics of Parkinson's disease using both cellular and animal models. Laura is now working on stem cell derived cerebral organoids in Dr. Madeline Lancaster lab at the MRC Laboratory of Molecular Biology in Cambridge, where she recently developed a new model to study the choroid plexus and the cerebrospinal fluid secretion in vitro. This model was published in Science (Pellegrini et al 2020a), has received the NC3R International Award (2021), and was recently used to study SARS-CoV-2 infection in the brain (Pellegrini et al 2020b). Laura's research using the choroid plexus organoid model is focused on the development of this brain region in humans, on secretion of disease-related biomarkers in the cerebrospinal fluid and on the role of this brain barrier in pathogen and drug entry to the brain.



## Peter J. Pereira Gray

TUESDAY, 17:30

Managing Partner and Chief Executive Officer of the Investment Division of the Wellcome Trust

Peter Pereira Gray is Managing Partner and Chief Executive Officer of the Investment Division of the Wellcome Trust. He has been a member of Wellcome's full Investment Committee for over 20 years and has joint accountability for the \$50 billion global unconstrained multi-asset investment portfolio, and the leadership of the Investment Division. Wellcome has delivered an annualised return of over 14% per annum since October 1985. Peter led Wellcome's successful initiative to obtain planning consent in January 2021 to extend its research facilities at Hinxton in South Cambridgeshire. The campus will become one of the largest of its type in the world.

Peter was co-chairman of the global Institutional Investors Roundtable (IIR) organisation from November 2018 until June 2021. During that time he led an initiative to aggregate investor capital to create a global healthcare innovation fund; this is ongoing. Peter is chairman of Urban&Civic plc, the UK's leading master-planner, and of Premier Marinas Ltd, the leading UK marina, boatyard and storage company. Peter is a member of the advisory Board for the Global Projects Centre at Stanford University, and an honorary vice president of the Cambridge University Land Society.



## Andrew Plump

TUESDAY, 10:20

President, Research & Development, Takeda Pharmaceutical Company Limited

Andrew Plump's career spans nearly 30 years in the pharmaceutical industry and academia from early research through regulatory approval and patient access.

Dr. Plump oversees Takeda's global R&D organization of more than 5,000 employees. Early in his tenure he orchestrated a multi-year strategic and cultural transformation that has resulted in a renewed focus on innovation, streamlined global footprint, prioritized therapeutic areas of focus, a rich network of partnerships and a modality-diverse portfolio of newly approved and promising late-stage development experimental therapies. He also championed efforts to build an exciting and sustainable early development and research pipeline, founded on strong translational science as well as platform capabilities in cell therapy, gene therapy and data sciences. Prior to Takeda, Dr. Plump served as head of Research & Translational Medicine, deputy to the president of R&D at Sanofi, based in Paris, France. Prior to Sanofi, Dr. Plump served as worldwide cardiovascular research head at Merck.



## Rab Prinjha

TUESDAY, 15:45

Head of Immunology Research Unit, GSK

Rab Prinjha leads the Immunology Research Unit. He cofounded the GSK Biology Council and is an elected fellow of the Academy of Medical Sciences and Senior Fellow of the Royal Society of Biology and cochair of the GSK Fellows Council. He represented GSK on the EU-EFPIA Board through which he chaired the Immunology SGG and earlier led the GSK collaboration with the Harvard Medical School Immune Diseases Institute. He serves on GSK Research Review Board and the OpenTargets, Varsity, Altius, Broad and Laboratory for Genomic Research Governance Boards. He sits on the Academy of Medical Sciences Council and served as a member of the Padlock Board of Directors until its acquisition by BMS in 2016. He was appointed to the UK MRC PSMB Board and is on the SAB of the MRC UK Human Genetics Unit. He is a co-founder and Innovation Board member of the Milner Therapeutics Consortium.

Previously, under his leadership the GSK Epigenetics DPU was responsible for many novel and industry leading discoveries in the area of exploring and exploiting epigenetic inhibitors in human disease treatment. Rab has published extensively with high impact papers in Cell, Science and Nature in the areas of immunology, oncology, epigenetics and neuroscience. Rab joined GSK from academia including a post-doc in developmental neuroscience at Guy's Hospital and PhD in molecular cellular immunology at UCL after a degree in Biotechnology at King's College London.



## Dr. Greg Raskin

WEDNESDAY, 09:50

Senior Vice President of Technology Development, Memorial Sloan Kettering Cancer Center

Dr. Gregory Raskin is the Senior Vice President of Technology Development at Memorial Sloan Kettering Cancer Center in New York City. In this role, he leads efforts to ensure that promising discoveries made in MSK's laboratories are further developed and commercialized. Prior to joining MSK in 2012, Greg worked for a decade as an investor in public and private biotechnology companies; for a few years as a management consultant to pharmaceutical companies; and briefly as a medical resident.

Greg is also a Lecturer at Yale University in New Haven, Connecticut, where he co-teaches an undergraduate seminar on biotechnology and drug development each year. He received his BA and MD degrees from Yale.



## Mike Rea

WEDNESDAY, 10:50

CEO & Founder, IDEA Pharma Ltd

Mike is CEO and Founder of IDEA Pharma and Protodigm. He is a pharma innovation protagonist, antagonist, and geek. Mike is the author of *Positioning Pharmaceuticals* and a contributor to Fortune, STAT, and Endpoints. He is recognized as an industry influencer — Global Power List: 20 in 2020 and 2021, the Top 20 inspirational medicine makers in biopharmaceuticals (The Medicine Maker); Top 10 Innovators in Pharma (PharmaPhorum); PharmaVOICE Red Jacket: 100 Most Inspiring People in Healthcare (2011, '13, '15 and '16, + lifetime Red Jacket award); and Global Power List 100 (Medicine Maker, the 100 most influential people in healthcare, 2017, 2018, 2019). Mike is also a Senior Fellow at the Milken Institute, an advisor to BioEthics International, and a Strategic Innovation Advisor at Nanoform. Mike created the industry standard annual Pharmaceutical Innovation and Invention index in 2010.



## Jim Reddoch

TUESDAY, 15:05

Executive Vice President, Co-Head Research & Investments and Chief Scientific Officer, Royalty Pharma plc

Dr. Reddoch joined Royalty Pharma in 2008 as Executive Vice President and Head of Research. He is now Chief Scientific Officer and Co-Head of Research & Investments, the group that sources and analyzes new investment opportunities and partnerships. In 2020, he started the Strategy & Analytics department to use large data sources more effectively in the firm's analyses and sourcing. Prior to joining Royalty Pharma, Dr. Reddoch was Head of Healthcare Research at FBR Capital Markets. Previously, Dr. Reddoch was a biotechnology analyst at Bank of America and CIBC World Markets. Dr. Reddoch serves on the board of Avillion, a London-based drug development company, and on Memorial Sloan Kettering Cancer Center's external review board for its Technology Development Fund. He is Vice Chairman of the Therapy Acceleration Program at the Leukemia & Lymphoma Society.

Dr. Reddoch has a BA from Furman University, a PhD in biochemistry and molecular genetics from the University of Alabama, and was a postdoctoral fellow at Yale University.





## David Redfern

Chief Strategy Officer, GlaxoSmithKline plc

TUESDAY, 09:15

David Redfern was appointed Chief Strategy Officer of GSK in May 2008 and is responsible for corporate development and strategic planning. In addition to his current role, since 2011 he has also been Chairman of the Board of ViiV Healthcare Ltd., a company controlled by GSK entirely focused on discovering, developing and commercializing medicines for HIV. He is a member of the GSK Leadership Team. He is also a director of the GSK Consumer Healthcare joint venture with Pfizer, and a non-executive director of the South African listed healthcare group, Aspen Pharmacare Holdings Ltd.

Previously, he was Senior Vice President, Northern Europe with responsibility for managing GSK's pharmaceutical businesses in that region and, prior to that, was Senior Vice President for Central and Eastern Europe. David joined GSK in 1994 and was Finance Director of the European business from 1999 to 2002.

David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.



## David M. Reese

Executive Vice President, Research and Development, Amgen

WEDNESDAY, 10:50

Dr. David M. Reese is executive vice president, Research and Development. In this role, Dr. Reese oversees Discovery Research, Global Development, Global Regulatory Affairs and Safety, as well as Global Medical. Dr. Reese joined Amgen in 2005 and has served in various leadership roles within the Research and Development organization. This includes most recently serving as Senior Vice President of Translational Sciences and Oncology where he oversaw the translation of Amgen's medicines from the lab into the clinic and the overall oncology strategy. Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and Chief Medical Officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization.

Dr. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco.



## Wolf Reik

Honorary Professor of Epigenetics at University of Cambridge; Director, Altos Labs Cambridge Institute

TUESDAY, 11:20

Professor Reik obtained his MD from the University of Hamburg, doing his thesis work with Rudolf Jaenisch and postdoctoral work with Azim Surani in Cambridge. He became a Fellow of the Lister Institute of Preventive Medicine at Cambridge and subsequently the Head of the Epigenetics Programme at the Babraham Institute in Cambridge, later serving as its Director. Wolf is a Fellow of the Academy of Medical Sciences, Fellow of the Royal Society, and a member of the Academia Europaea. Since March 2022, he is Director of the Altos labs Cambridge Institute.

The research interests of his lab are in epigenetic reprogramming during mammalian development and its role in stem cell biology, inheritance, and ageing. Their current work addresses the mechanisms of genome-wide demethylation in the mammalian germ line, links between reprogramming, zygotic genome activation and pluripotency, epigenetic regulation of cell fate decisions in early development, and the role of epigenetic mechanisms in ageing. The lab also develops new epigenomics technologies especially in single cells.



## Michael Secora

Chief Financial Officer, Recursion Pharmaceuticals, Inc.

WEDNESDAY, 14:00

Michael Secora, PhD, has served as our Chief Financial Officer since March 2020. Prior to joining Recursion Pharmaceuticals, Inc., Dr. Secora worked at Laurion Capital Management, as an asset manager based in New York City from July 2010 to February 2020, where he was Managing Director and Head of Capital Markets and Venture. During his time at Laurion, he developed, executed and managed fundamentally grounded investment strategies as well as built business partnerships and technological infrastructure for investing in event-driven, fundamental and macroeconomic contexts.

Dr. Secora received his PhD from Princeton University in Applied and Computational Mathematics and B.S. in Mathematics and Physics from Massachusetts Institute of Technology.



## Joanna Shields

CEO, BenevolentAI

WEDNESDAY, 13:35

Tech industry veteran Joanna Shields is currently CEO of BenevolentAI, a leading clinical-stage AI drug discovery company using AI to develop more effective medicines. She serves as Co-Chair of the Global Partnership on AI (GPAI), sits as a Commissioner on the Oxford Commission for AI and Good Governance (OXCAIGG) and has served as the UK's first Minister for Internet Safety and Security, Chair & CEO of TechCityUK and non-exec of the London Stock Exchange Group. In 2014, Shields founded WeProtect, a global alliance working to protect children from online abuse.

In 2014, she was appointed OBE for services to digital industries and made a Life Peer in the House of Lords.



## Pascal Soriot

CEO, Astra Zeneca

WEDNESDAY, 08:30

Pascal brings a passion for science and medicine as well as significant experience in established and emerging markets, strength of strategic thinking, a successful track record of managing change and executing strategy, and the ability to lead a diverse organisation. He served as Chief Operating Officer of Roche's pharmaceuticals division from 2010 to September 2012 and, prior to that, CEO of Genentech, a biologics business, where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in numerous major companies around the world. He is a doctor of veterinary medicine (École Nationale Vétérinaire d'Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.



## Timothy A. Springer

Latham Family Professor, Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School; Senior Investigator, Program of Cellular & Molecular Medicine, Boston Children's Hospital

TUESDAY, 17:00

Timothy A. Springer, PhD is the Latham Family Professor at the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Senior Investigator at the Program of Cellular and Molecular Medicine at Boston Children's Hospital.

He is a world leader in structural biology and immunology. He discovered many of the adhesion receptors in the immune system with monoclonal antibodies, then cloned and functionally and structurally characterized them. He was the first to demonstrate that lymphocytes and leukocytes had adhesion molecules. His work on these receptors has advanced to characterizing their interactions and allosteric transitions by x-ray crystallography, electron microscopy, and laser tweezers force spectroscopy. In recognition of this work, he received the Canada Gairdner International Award in 2019, and was recently awarded the Biophysical Society's Founder's Award in 2021. He is a founder and private investor in biopharmaceutical ventures, including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences, and Ab Initio Biotherapeutics. His research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and immune diseases.

Notably, he also co-founded the Institute for Protein Innovation: a non-profit to advance entrepreneurship and innovation in protein therapeutics and open-source antibodies and small molecules.



## Otello Stampacchia

Founder, Omega Fund Management, LLC

TUESDAY, 13:45

Otello founded Omega Funds in 2004 and leads the firm's investor relations and strategic initiatives. He is a member of the firm's investment committee and is also heavily involved in a number of Omega's therapeutic areas of interest, particularly in oncology, rare diseases and inflammatory disorders.

Previously, Otello was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlInvest Partners. Before AlInvest, he was the portfolio manager of the Lombard Odier Immunology Fund, a \$3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs, prior to which he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.



## Anthony Sun

President and CEO, Zentalis Pharmaceuticals

WEDNESDAY, 09:10

Anthony has played an active role across the life science industry since 2002 and currently serves as President and CEO for Zentalis Pharmaceuticals. From 2002 until 2015, he was at Aisling Capital and Perseus-Soros Biopharmaceutical Fund, private equity firm dedicated to the life sciences, during which he held multiple positions most recently as Partner. Dr. Sun holds a BS in Electrical Engineering from Cornell University, an MD from Temple University School of Medicine, an MBA from The Wharton School at the University of Pennsylvania. He trained in internal medicine at the Hospital of the University of Pennsylvania and was board certified in internal medicine.



## Stephen J Toope

Vice Chancellor, University of Cambridge

TUESDAY, 09:00

Professor Stephen J Toope OC, LL.D. is 346th Vice-Chancellor of University of Cambridge, and the first non-UK national to hold the post. He was Director of the Munk School of Global Affairs at the University of Toronto, and President, the University of British Columbia. A former Dean of Law at McGill University, Professor Toope was also Chair of the United Nations Working Group on Enforced and Involuntary Disappearances.

Professor Toope publishes in global journals on human rights, international dispute resolution, international environmental law, the use of force and international legal theory, and has lectured at universities around the world.

His current book project with Professor Jutta Brunnée explores mechanisms and processes fostering stability and change in international law.



## Chris Torrance

Chair, PhoreMost Limited

TUESDAY, 12:10

Dr. Chris Torrance is a cancer researcher and serial entrepreneur. In 2007 he founded Horizon Discovery to translate advances in human genome editing into a range of research tools and services to accelerate the discovery of new and improved 'Personalized Medicines'. By 2014 Dr. Torrance and his colleagues had built Horizon into the fastest growing Biotech company in the UK. In the same year, the company listed on the London Stock Exchange with over 100 commercial and scientific staff and significant deal-flow with the pharmaceutical Industry, for which Horizon received the Queens Award for International Trade.

Frustrated by the unmet need for many diseases and the Pharma industry's focus on easy targets, rather than the right targets, Dr. Torrance founded PhoreMost Ltd in 2014 and served as CEO until taking on the role of Chair in March 2022. PhoreMost is a company dedicated to first-in-class targets and focuses on drugging 'Undruggable' targets using a new technology called SITESEEKER® that systematically identifies cryptic drug sites throughout the human proteome and ties them to useful therapeutic functions.



# Exhibitors



Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, improving wellbeing and disease management globally and empowering health professionals to provide life-changing answers for patients and their families.

Congenica's world-leading software enables genomic data analysis at scale, performing analysis more than 20-times faster, reducing genomic interpretation costs by up to 95% and enabling higher diagnostic yields than previously possible.

Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica has a global footprint supporting leading diagnostic laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.

[congenica.com](http://congenica.com) / [@Congenica](https://twitter.com/Congenica)



EpiTopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK.

We are a global leader in exploiting a novel class of untapped tumour-specific antigens (TSAs), Cryptigen™ TSAs, which we believe represent the major opportunity for T cells to control cancer. We intend to develop products using the most appropriate modality available for the opportunity and capable of treating a broad patient population. The company has backing from leading international life sciences investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, and the Fonds de solidarité FTQ.

[epitopea.com](http://epitopea.com)



Founded in Cambridge, UK, in 2014, Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. By combining frontier AI technology with deep drug discovery and development expertise, Healx is accelerating the pace, increasing the scale and improving the chance of success of rare disease treatment development. For more information about Healx's work and team, visit [www.healx.io](http://www.healx.io) or follow on Twitter and LinkedIn.

[healx.io](http://healx.io) / [@healx](https://twitter.com/healx)



Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in clinical microbiome analysis linked to patient phenotype for the discovery of new bacterial medicines and biomarkers. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, and University of Adelaide in Ulcerative Colitis.

[microbiotica.com](http://microbiotica.com) / [@MicrobioticaLtd](https://twitter.com/MicrobioticaLtd)



Nuclera is the leading pioneer in making biology accessible through its eProtein™ desktop bioprinting technology. Headquartered in Cambridge, UK, Founded in 2013 by four PhD students, Nuclera has since grown to 60 employees across two continents as it delivers on its founders' vision. Through desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins. Three exciting Nuclera technologies protected by 45+ patents enable Nuclera's desktop bioprinter: eProtein™ synthesis, eDNATM synthesis, and eDrop™ digital microfluidics. The combination of these technologies in a deployable desktop bioprinting platform create an unprecedented one-stop shop ecosystem that enables Nuclera to provide consistent biological workflows, products, and information to its customers.

[nuclera.com](http://nuclera.com)



Turbine is the world's only biotech solving complex disease(s) with Simulated Cells™. It was founded to find the right treatment for every patient by combining simulation with machine learning. Our white-box modelling process runs experiments at computational scale to overcome the limitations of current biological data generation methods. Unique insights on mechanisms and associated biomarkers, coupled with proprietary mechanistic validation assays allow us to find novel targets & better position existing drug candidates at scale.

[turbine.ai](http://turbine.ai) / [linkedin.com/company/10241953](https://www.linkedin.com/company/10241953)

# Wellcome Genome Campus

The Wellcome Genome Campus is home to some of the world's leading institutes and organisations in the field of genomics and computational biology. As well as undertaking research, organisations on Campus provide bioinformatics resources for the global scientific community, and deliver vital training in genomics and biodata to scientists and clinicians. The Campus is also home to several life science companies, adding to the diverse and exceptional scientific community, and uniquely positioning it at the interface of research and industry.

The Campus' purpose is to deliver life-changing science with the reach, scale and imagination necessary to solve some of humanity's greatest health challenges. It was founded with two now-world-leading research institutes – the Wellcome Sanger Institute and the EMBL-European Bioinformatics Institute – in the early 1990s at the start of the Human Genome Project, an ambitious global project to sequence the human genome for the first time, and make this data freely available. The Sanger Institute produced around one third of the first human genome sequence over ten years, and the EMBL-EBI developed tools and resources ensuring that this data could be distributed and made publicly accessible.

Since then, the next generation sequencing revolution has enabled genomic data to be produced quickly and cheaply on a previously unimagined scale, changing the model for current and future Campus research. Now home to over 2,000 staff, there are ambitious plans to grow the Campus over the next 25 years, extending its facilities to increase its community of scientific leaders.

Accelerating Bio-Innovation is taking place at the Wellcome Genome Campus Conference Centre, part of which – Hinxton Hall – dates from 1748. The Hinxton Hall estate, first mentioned in records in 1506, was bought by the Wellcome Trust in 1992. Wellcome meticulously restored the Georgian Hall and transformed the old stable block and kitchen garden into a purpose-built conference centre that opened in 1998. The next set of major works were finished in 2015, creating the Conference Centre that you see today. The venue is an integral part of a genomics learning, training and engagement programme called Wellcome Genome Campus Connecting Science. The Conference Centre provides meeting, networking and relaxation spaces conducive to learning and sharing, thus contributing to Connecting Science's mission to enable everyone to explore genomic science and its impact on research, health and society.

# Fitzwilliam Museum

The Fitzwilliam Museum was founded by a bequest of Richard, Viscount Fitzwilliam of Merrion, in 1816. The Fitzwilliam bequest included 144 pictures, among them Dutch paintings he inherited through his maternal grandfather, Sir Matthew Decker, and masterpieces by Titian, Veronese and Palma Vecchio that he bought from the Orléans sales in London. The Museum now houses over half a million artefacts from around the world. See everything from Egyptian coffins to illuminated manuscripts; rare coins to paintings by Italian masters; ancient pottery to suits of shiny armour. It's 2022 exhibition programme includes Hockney's Eye: The Art and Technology of Depiction (15 March – 29 August) and True to Nature: Open-air Painting in Europe 1780-1870 (3 May – 29 August).

[www.fitzmuseum.cam.ac.uk/about-us/founding-the-fitzwilliam](http://www.fitzmuseum.cam.ac.uk/about-us/founding-the-fitzwilliam)

[www.fitzmuseum.cam.ac.uk/about-us/history-of-the-building-and-collections](http://www.fitzmuseum.cam.ac.uk/about-us/history-of-the-building-and-collections)





# King's College

Settled in the heart of Cambridge, on the banks of the river Cam, is one of the most famous and photographed colleges in the country, King's College. The King's College of Our Lady and St Nicholas in Cambridge was founded in 1441 by King Henry VI and munificently endowed. The Founder's statutes provided for a Provost and seventy poor scholars. Scholarships were restricted to Etonians, but a few pensioners and Fellow commoners from other schools were admitted from the middle of the sixteenth century. The first female Fellow of King's was elected in 1970 and female students were first admitted to King's in 1972. These historic buildings are known worldwide for their architecture, design and splendour, providing a blend of traditional and modern facilities.

## King's College Chapel and Music

King's College Chapel is the oldest surviving building within the College site and perhaps the most iconic building in Cambridge. Work on this Chapel only started five years after King's College was founded by Henry VI in 1441. King's College Chapel plays a central role in College life. It is the place where new students matriculate, where Fellows are admitted, and where the Choir sings services nearly every day. On Christmas Eve King's College broadcast A Festival of Nine Lessons and Carols live on radio to millions worldwide and record television services for both Christmas and Easter.

The Harrison & Harrison organ in King's College Chapel is, like the College Choir, famous the world over. The organ case with gilded pipework, which surmounts the 16th century screen, is a striking feature of nearly every depiction of the interior of the Chapel, while the instantly recognisable sounds of the instrument have become inextricably associated with those of the Choir. Many of today's leading musicians have held the position of Organ Scholar at King's. The organ fulfils an important role in the religious and musical life of the College while also serving as an educational resource; as such it supports all of the College's statutory aspirations: 'education, religion, learning and research'



### Organ Recital

by Paul Grealley

King's College, Cambridge

Paul Grealley, organ scholar at King's College, Cambridge, was made Fellow of the Royal College of Organists as a teenager, winning a total of seven prizes in the RCO organ diplomas. Before reading music at Cambridge, he was organ scholar at Pinner Parish Church and joint first study composer and organist at the Junior Royal Academy of Music. His several composition accolades include the BBC Proms Inspire competition (his works were performed by the BBC Singers and Aurora Orchestra, broadcast on BBC Radio 3) and publication by Editions Musica Ferrum. Paul is also an accomplished pianist (ARSM distinction), drummer (Grade 8 distinction) and jazz pianist.

TUESDAY, 19:15







# Delegates

**Mateo Aboy**  
Principal Research Scholar, LML,  
University of Cambridge

**Nikolai Ahrens**  
CEO, LifeScience ORG

**Iraj Ali**  
CEO, Achilles Therapeutics plc

**Tauhid Ali**  
Director, MonoGen Ltd

**Andrew Allen**  
President & CEO, Gritstone bio

**Tim Allsopp**  
CTO, Skylark Therapeutics Ltd

**Barbara Angehrn**  
CBO, Stepstone Pharma

**Lisa Anson**  
CEO, Redx Pharma

**Michael Anstey**  
Partner, Cambridge Innovation  
Capital

**Sakae Asanuma**  
CEO & President, Taiho Ventures, LLC

**Houman Ashrafi**  
Managing Partner, SV Health  
Managers

**Wolfgang Aulitzky**  
President & Medical Director,  
Open Medical Institute

**Sandy Balkin**  
SVP Strategy and Analytics,  
Royalty Pharma

**Csaba Bardossy**  
Head of Legal, Turbine

**Laurence Barker**  
Partner, SV Health Investors

**Deborah Baron**  
SVP, Worldwide Business  
Development, Pfizer

**Jonathan Barr**  
CFO, Atomwise

**Alan Barrell**  
Chairman, Cambridge Learning  
Gateway

**Roberto Bellini**  
President & CEO, BELLUS Health Inc

**Edward Benthall**  
Chairman, Cambridge Innovation  
Capital

**David Berglund**  
Founder, ITB

**Erik Berglund**  
CEO & Associate Professor, ITB-MED

**Timothy Bertram**  
CEO, ProKidney

**Maina Bhaman**  
Partner, Sofinnova Partners

**Kate Bingham**  
Managing Partner, SV Health  
Managers

**Robert Blum**  
President & CEO, Cytokinetics

**Keith Blundy**  
Director & CEO, Storm Therapeutics

**Sir Leszek Borysiewicz**  
Chair, Cancer Research UK

**Cathy Boucher**  
Translational Research Programme  
Manager, University of Cambridge

**Chas Bountra**  
Professor of Translational Medicine,  
Oxford University

**Emily Boyce**  
Knowledge Exchange Manager,  
Babraham Institute

**Allan Bradley**  
Professor & Director of Studies,  
University of Cambridge

**Clare Bryant**  
Professor of Innate Immunity,  
University of Cambridge

**Fabian Buller**  
CBO, Neurimmune AG

**Ana Camelo Stewart**  
Coordinator MPhil Therapeutic  
Sciences, University of Cambridge

**Beverley Carr**  
CBO, Amphista

**Kathryn Chapman**  
Deputy Director, Milner  
Therapeutics Institute, University of  
Cambridge

**Simon Chell**  
Executive Director, Discovery  
Biology, AstraZeneca

**Michael Chen**  
CEO, Nuclera

**Jason Chin**  
Scientific Programme Leader,  
MRC LMB

**David Chiswell**  
Chairman, EpsilonGen Ltd

**Isaac Ciechanover**  
Partner, Polaris Partners

**Carmine Circelli**  
Senior Investment Manager,  
British Patient Capital

**Fred Cohen**  
Chairman, Monograph Capital

**Simon Cook**  
Interim Institute Director,  
Babraham Institute

**Craig Cowan**  
Investment Director, Baystone

**Terrance Coyne**  
EVP & CFO, Royalty Pharma

**Nick Crabbe**  
Programme Director, Scientific  
Affairs, NICE

**Frank Craig**  
CEO, Sphere Fluidics Limited

**Cristina Crespo**  
Research Associate, University of  
Cambridge

**Craig Crews**  
Executive Director, Yale University  
Center for Molecular Discovery

**Margaret Crotty**  
CEO, John Snow, Inc

**Habib Dable**  
Investor & Former CEO, Acceleron

**Bassil Dahiyat**  
President & CEO, Xencor

**Robert de Jonge**  
VP Head of Corporate Development,  
Mestag Therapeutics

**Louis DeGennaro**  
President & CEO,  
The Leukemia & Lymphoma Society

**Robert Denison**  
Chief Information Officer, Congenica

**Dan DiPietro**  
Founding Partner, Aceras

**Ann Doherty**  
Head of Business Innovation,  
AstraZeneca

**Tammy Dougan**  
GSK Relationship Manager,  
University of Cambridge

**Stephen Dowd**  
Head of Business Development,  
Europe, RallyBio

**William Doyle**  
Executive Chairman, Novocure Ltd

**Shiva Dustdar**  
Head of Innovation Finance Advisory  
Division, EIB

**Nick Eliovits**  
Co-Founder, DermBiont

**Phil Elstob**  
Commercialisation Director,  
Cambridge Enterprise

**Mark Evans**  
Professor of Diabetic Medicine,  
University of Cambridge

**Matthias Evers**  
Senior Partner, McKinsey &  
Company, Inc

**Douglas Fambrough**  
ex-CEO, Dicerna Pharmaceuticals

**Sadaf Farooqi**  
Professor, University of Cambridge

**Anne Ferguson-Smith**  
ProVC for Research, University of  
Cambridge

**Mark Fidock**  
VP & Head of Diagnostic  
Development Unit, PMB, Astra  
Zeneca

**Mike Fisher**  
VP & Head of Business Development,  
Oncimmune

**Alexandria Forbes**  
CEO, MeiraGTX

**Sally-Ann Forsyth**  
CEO, Stevenage Bioscience Catalyst

**Alicia Gailliez**  
Business Development Manager,  
One Nucleus

**Jochen Gann**  
Head of Corporate Finance and  
M&A, Boehringer Ingelheim

**Manas Gautam**  
Investor, Morgan Stanley Investment  
Management

**Thomas Geninatti**  
Director, Corporate Development,  
Gilead Sciences

**Cedric Ghevaert**  
Professor in Transfusion Medicine,  
University of Cambridge

**Giammaria Giuliani**  
Entrepreneur, Royalty Pharma

**Germano Giuliani**  
Investor, MGG Capital

**Simon Goldman**  
Investment Director,  
UCL Technology Fund

**Jaime Gomez**  
CEO, Nefro Health

**Henry Gosebruch**  
EVP & Chief Strategy Office, AbbVie

**Julian Gough**  
Programme Leader, MRC LMB

**Arjun Goyal**  
Co-Founder & Managing Director,  
Vida Ventures

**Anne Grahl**  
Analyst, Pureos Bioventures

**Fabio Grassi**  
Chairman, MV BioTherapeutics

**Bill Grau**  
Vice President, Strategy & Analytics,  
Royalty Pharma

**Ivan Griffin**  
COO & Co-Founder, BenevolentAI

**George Grofik**  
SVP, Investor Relations &  
Communications, Royalty Pharma

**Jane Grogan**  
CSO, Graphite Bio –  
South San Francisco, CA

**Phill Gross**  
Co-Founder & Managing Director,  
Adage Capital Management

**Simon Gruber**  
Senior Associate,  
Pharmakon Advisors, LP

**Tim Guilleims**  
CEO, Healx Limited

**Matt Hall**  
Senior Scientific Officer, EMBL-EBI

**Mervyn Hall**  
Senior Director, Aetion

**Stig Hansen**  
Co-Founder & CEO,  
Carmot Therapeutics

**Jia-Yi Har**  
Managing Director, Cathay Capital

**Mary Lynne Hedley**  
Sr Scientific Fellow, Broad Institute

**Abraham Heifets**  
CEO, Atomwise

**Tony Hickson**  
Chief Business Officer,  
Cancer Research UK

**Susan Hill**  
CEO, Mestag Therapeutics

**Andrew Hindman**  
CFO, Theravance Biopharma

**Chris Hite**  
EVP & Vice Chairman,  
Royalty Pharma

**Axel Hoos**  
CEO, Scorpion

**Andrew Hopkins**  
CEO, Exscientia

**Anne Horgan**  
Partner, Cambridge Innovation  
Capital

**Jenny Horsfield**  
SVP & CBO, Carrick Therapeutics

**James Huntington**  
Professor of Molecular Haemostasis,  
University of Cambridge

**Marko Hyvonen**  
Research Group Head,  
University of Cambridge

**Laura Itzhaki**  
Co-Director, Cambridge Academy  
of Therapeutic Sciences;  
Head of Pharmacology,  
University of Cambridge

**Stephen Jackson**  
Senior Group Leader & Head of  
CRUK Laboratories, Gurdon Institute,  
University of Cambridge

**David Jenkinson**  
CSO, The Brain Tumour Charity

**Allison Jaynes-Ellis**  
CEO, Avillion LLP

**Robert Johnson**  
CEO, Adrestia

**Keith Jones**  
Manager of Commercialization,  
Babraham Institute

**Michelle Jones**  
Vice President, Strategy &  
Operations, Astex Pharmaceuticals

**Peter Joyce**  
CEO, Grey Wolf Therapeutics

**Arthur Kaser**  
University Chair of Gastroenterology,  
University of Cambridge

**Steven Kaye**  
Company Director,  
Baystone Associates

**Arik Kershenbaum**  
Fellow, Girton College,  
University of Cambridge

**Rabia Khan**  
CEO, Ladder Therapeutics

**Aftab Kherani**  
CMO & Managing Director,  
Ajax Health

**Gene Kinney**  
President & CEO,  
Prothena Corporation plc

**Ulrich Kinzel**  
Managing Director, goetzpartners  
Corporate Finance GmbH

**Nina Kjellson**  
General Partner, Canaan

**Sara Klymkowsky**  
Vice President, Research &  
Investments, Royalty Pharma

**Mark Kotter**  
Honorary Consultant Neurosurgeon  
& Founder, BitBio, University of  
Cambridge

**Tony Kouzarides**  
Director & Co-founder; Senior Group  
Leader, Milner Therapeutics Institute;  
Gurdon Institute

**Angela Kukula**  
Director of Business & Innovation,  
The Institute of Cancer Research

**Peter Lafer**  
Principal, General Atlantic

**Fouzia Laghrissi-Thode**  
CEO, DalCor Pharmaceuticals

**Angus Lauder**  
Director of Business Development,  
STORM Therapeutics Ltd

**Araminta Ledger**  
Deputy Executive Director,  
Cambridge University Health  
Partners

**Melanie Lee**  
CEO, LifeArc

**Pablo Legorreta**  
Founder & CEO, Royalty Pharma

**Mark Lewisohn**  
Deputy Chair of Council,  
University of Cambridge

**Catherine Lindon**

Associate Professor,  
University of Cambridge

**Vivian Liu**

VP, Research & Investments,  
Royalty Pharma

**George Lloyd**

EVP Investments & General Counsel,  
Royalty Pharma

**Ted Love**

President & CEO,  
Global Blood Therapeutics

**Chris Lowe**

Co-Director of Cambridge Academy  
of Therapeutic Sciences;  
Emeritus Professor of Biotechnology,  
University of Cambridge

**Chris Love**

Head of Technology & Innovation,  
Horizon Discovery

**Jan Löwe**

Director, MRC Laboratory of  
Molecular Biology

**Jon Lyon**

Scientific Director & GSK Senior  
Fellow, GlaxoSmithKline

**Matthew Lyons**

VP, Royalty Pharma

**John MacDonald**

VP Venture & Financial Alliances,  
ICON

**Ankit Mahadevia**

CEO, Spero Therapeutics

**Thomas Mander**

CEO, Domainex Ltd

**Sally Mardikian**

Director, Business Development,  
AstraZeneca UK Limited

**Osman Mardin**

Managing Director, Sardis Capital

**Anita Marguerie de Rotrou**

Head of Office for Translational  
Research, University of Cambridge

**Jay Markowitz**

Senior Partner, Arch Venture Partners

**Christine Martin**

Interim Head of Seed Funds,  
Cambridge Enterprise

**Niall Martin**

CEO, Artios

**Steve Martin**

VP, Biopharm Discovery, GSK

**Charlie Mason**

Account Director, IDEA Pharma

**Shyam Masrani**

Principal, Medixi

**Patrick Maxwell**

Head of the School of Clinical  
Medicine, University of Cambridge  
School of Clinical Medicine

**Tom McCarthy**

Chairman, M:M Bio Ltd

**Donnie McGrath**

Chief Corporate Strategy and  
Business Development, Biohaven

**Kishen Mehta**

Portfolio Manager, Averill

**Jason Mellad**

CEO, Start Codon

**Eric Mertz**

VP, General Manager EU, Aetion

**Su Metcalfe**

CEO, LiFNano Therapeutics

**Sohaib Mir**

Senior Investment Principal, LifeArc

**Hitoshi Miyakoshi**

Investment Director,  
Taiho Ventures LLC

**Louise Modis**

CSO, Mogrify

**Alan Moodie**

Life Sciences Advisor, Independent

**Jon Moore**

CEO, Epitopea Ltd

**Michael Moritz**

Investor, Morgan Stanley

**Timothy Morris**

COO/CFO, Humanigen, Inc

**Matthias Muellenbeck**

SVP, Head Global BD & Alliance  
Management, Merck Healthcare  
KGaA

**Siddhartha Mukherjee**

Associate Professor of Medicine,  
Columbia University

**Padraig Mulcahy**

Education Programme Manager,  
Cambridge Academy of Therapeutic  
Sciences

**Mike Murphy**

Portfolio Manager, Meltwind

**Andrew Murray**

Professor of Metabolic Physiology,  
University of Cambridge

**Szabolcs Nagy**

CEO & Founder, Turbine

**Andy Neely**

ProVC, Enterprise & Business  
Relations, University of Cambridge

**Laura Nelson Carney**

Equity Investment Analyst, Capital  
Group

**Alice Newcombe-Ellis**

Founding Partner,  
Ahren Innovation Capital

**Pete Newham**

VP Safety Sciences, AZ

**Vlad Nikolenko**

VP Research & Investments,  
Royalty Pharma

**Oleg Nodelman**

Founder and Portfolio Manager,  
EcoR1 Capital

**Marc O'Reilly**

VP Molecular Sciences, Astex  
Pharmaceuticals

**Colin Orford**

Head of Drug Development  
Consulting service, ICON PLC

**Jane Osbourn**

CSO, Alchemab Therapeutics Ltd

**Roisin Owens**

Professor of Bioelectronics,  
University of Cambridge

**Terry Parlett**

Commercialisation Director,  
Cambridge Enterprise

**Meghana Patel**

Executive Manager, Cambridge  
Academy of Therapeutic Sciences

**Sharon Peacock**

Professor of Public Health &  
Microbiology/Director, University  
of Cambridge Department of  
Medicine/COG-UK

**Laura Pellegrini**

Postdoctoral scientist, MRC-LMB

**Peter Pereira Gray**

CEO, The Wellcome Trust

**Trevor Perrior**

Consultant, Excellium Consulting

**Sir Keith Peters**

Emeritus Regius Professor of Physic,  
University of Cambridge

**Anne Phelan**

CSO, BenevolentAI

**Anna Philpott**

Head of the School of Biological  
Sciences, University of Cambridge

**Andrew Plump**

President, Research & Development,  
Takeda Pharmaceutical

**Michael Price**

Manager, VJAM LLC

**Rab Prinjha**

Head of Immunology Research Unit,  
Research, R&D, GSK

**Brad Prosek**

President, All Terrain Partners LLC

**Laura Quock**

Director, Corporate Development,  
Gilead Sciences

**Geoff Race**

President,  
Minerva Neurosciences Inc

**Daniel Rankin**

Head of Global Portfolio and  
Product Strategy, Sobi

**Greg Raskin**

VP, Memorial Sloan Kettering  
Cancer Center

**Adrian Rawcliffe**

CEO, Adaptimmune

**Mike Rea**

CEO, IDEA Pharma

**Jill Reckells**

CEO, RxCelerate Ltd

**Jim Reddoch**

EVP, Co-Head Research &  
Investments and CSO,  
Royalty Pharma

**David Redfern**

Chief Strategy Officer, GSK

**David Rees**

CSO, Astex

**David Reese**

EVP, Amgen, Research and  
Development

**Wolf Reik**

Director, Altos Labs

**Laurence Reilly**

Consultant, Royalty Pharma

**Caroline Reynolds**

Impact Facilitator,  
University of Cambridge

**Juraj Rievaj**

Senior Research Facilitator,  
Cambridge Academy of Therapeutic  
Sciences

**Rory Riggs**

CEO, Cibus US LLC

**Charles Roberts**

Co-founder, Freenome, Inc

**Mat Robinson**

VP Translational Biology,  
Microbiotica

**Mike Romanos**

CEO, Microbiotica

**Kristin-Anne Rutter**

Director, Cambridge University  
Health Partners

**Becky Saenz**

Executive Director, Alianza médica  
para la salud

**Alex Samoshkin**

Translational Research Programme  
Manager, University of Cambridge

**Ritwick Sawarkar**

Group Leader, MRC,  
University of Cambridge

**Kenneth Seamon**

Director Science Development &  
Collaboration, CRUK Cambridge  
Cancer Centre, University of  
Cambridge

**Michael Secora**

CFO, Recursion

**Nigel Sheail**

Global Head M&A and BD&L,  
Novartis International AG

**Jesse Shefferman**

CEO, Protara Therapeutics

**Chris Sheldon**

VP & Head of Investor Relations,  
AstraZeneca

**David Sheppard**

CSO, Locki Therapeutics

**Joanna Shields**

CEO, BenevolentAI

**Oodaye Shukla**

Vice President, Strategy & analytics,  
Royalty Pharma

**Carmen Smith**

Administrator, Cambridge Academy  
of Therapeutic Sciences

**Ken Smith**

Head of Department of Medicine,  
University of Cambridge

**Rolf Soderstrom**

CFO, Syncona

**Pascal Soriot**

CEO, AstraZeneca

**Christopher Spooner**

CEO, Sinclair Pharma

**Timothy Springer**

Latham Family Professor, Senior  
Investigator, Boston Children's  
Hospital/Harvard Medical School

**Catherine Stace**

Director of Business Development,  
Domainex

**Austin Stack**

Portfolio Manager,  
Viking Global Investors LP

**Otello Stampacchia**

Managing Partner, Omega Funds

**Brian Stephenson**

CFO, BridgeBio

**Adam Stoten**

SVP Academic Partnerships,  
Evotec (UK) Ltd

**Alejandra Struck Creel**

Deputy Director, AMSA Alianza  
Medica para la Salud

**Anthony Sun**

CEO, Zentalis Pharmaceuticals, Inc

**Kristof Zsolt Szalay**

CTO & Founder, Turbine

**Paul Peter Tak**

President & CEO, Candel  
Therapeutics

**Clara Tang**

Alliance Strategy Manager, Healx

**Robert Tansley**

Partner, Cambridge Innovation  
Capital

**Christopher Tapper**

Senior Associate, Cambridge  
Innovation Capital

**Remi Terranova**

Associate Director, Novartis  
Institutes for Biomedical Research  
(NIBR)

**Luke Thomas**

Senior Scientist, Adrestia  
Therapeutics

**Iain Thomas**

Head of Life Science,  
Cambridge Enterprise

**Claire Thompson**

CEO, Agility Life Sciences

**Tamas Miklos Torok**

Head of Business Development,  
Turbine

**Chris Torrance**

Founder & Chair, PhoreMost Ltd

**Marek Tyl**

Scientific Advisor, Takeda

**Marshall Urist**

EVP & Co-Head, Research &  
Investments, Royalty Pharma

**Tatiana Verdon**

Event Manager, Cambridge  
Academy of Therapeutic Sciences

**Daniel Veres**

CSO & Founder, Turbine

**Jennifer Versnel**

Director, MPhil in Therapeutic  
Sciences and Policy,  
University of Cambridge

**Stefan Vitorovic**

Co-Founder & Managing Director,  
Vida Ventures

**Alexander Von Perfall**

Vice President, IR & Public Affairs,  
Royalty Pharma

**Jay Walker**

CEO Apiject, Curator TEDMED,  
Apiject

**Gregory Weinhoff**

CFO, Centessa Pharmaceuticals

**James Westcott**

CEO, ThirtyFiveBio Ltd

**Teri Willey**

Managing Director, IU Ventures

**Anna Williamson**

Executive Director, Pharma  
Partnering, Roche

**Anne Willis**

Co-Director, Cambridge Academy  
of Therapeutic Sciences;  
Director, MRC Toxicology Unit,  
University of Cambridge

**Amy Wilson**

Associate Director, Genetic  
Toxicology & Cambridge Alliance on  
Medicine Safety (CAMS) Manager,  
AstraZeneca

**Richard Wyse**

Director of Research and  
Development, Cure Parkinsons

**Uri Yaron**

Independent

**Leopoldo Zambelletti**

Director, Touchlight Plc

**Brett Zbar**

Managing Director, General Atlantic



Cambridge Academy  
of Therapeutic Sciences

**ROYALTY PHARMA**



**UNIVERSITY OF  
CAMBRIDGE**